Want to join the conversation?
Biopharmaceutical giant $BMY said it agreed to buy private biotechnology company Cardioxyl Pharmaceuticals in a deal where $BMY will pay $300MM upfront and about $1.775Bil upon achieving certain milestones. The deal is expected to be dilutive to $BMY's 2015 GAAP EPS by about $0.12, with minimal dilution to non-GAAP EPS in both 2015 & 2016.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.